GleamWall
中文EN

SGMT Sagimet Biosciences Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1400118 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.5%
ROA-26.0%
ROIC (approx.)-43.4%
Asset turnover—

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.00x
Current ratio6.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$16.34M$11.54M$7.00M$6.73M$9.73M$7.25M$15.34M$14.22M
SG&A expense$5.23M$4.28M$4.72M$4.03M$4.60M$4.68M$4.52M$3.98M
Operating income-$21.57M-$15.82M-$11.71M-$10.77M-$14.33M-$11.93M-$19.86M-$18.20M
Net income-$19.15M-$13.95M-$10.65M-$9.57M-$12.91M-$10.39M-$18.18M-$16.20M
EPS (basic)-0.31-0.26-0.33—-0.40-0.32-0.56—
EPS (diluted)-0.31-0.26-0.33—-0.40-0.32-0.56—
Weighted avg. shares (diluted)62.34M53.11M32.56M—32.46M32.20M32.20M—
Balance sheet
Cash & equivalents$110.96M$165.90M$36.63M$35.02M$32.50M$42.33M$64.72M$75.84M
Short-term investments$125.44M$74.23M$67.91M$78.10M$84.20M$83.08M$79.85M$75.41M
Current assets$240.72M$243.99M$107.72M$116.40M$119.48M$127.20M$146.07M$152.77M
Total assets$282.09M$263.43M$107.75M$116.48M$128.40M$137.41M$146.17M$160.26M
Current liabilities$37.98M$5.42M$5.30M$5.10M$9.15M$7.25M—$4.45M
Total liabilities$39.91M$7.28M$5.30M$5.10M$9.15M$7.25M$7.18M$4.45M
Shareholders' equity$242.18M$256.15M$102.46M$111.38M$119.25M$130.16M$138.99M$155.81M
Cash flow statement
Operating cash flow-$12.11M-$11.10M-$8.61M-$11.83M-$10.18M-$9.10M-$14.54M-$11.02M
Investing cash flow-$73.25M-$24.02M$10.22M$14.36M$75,000-$13.29M$3.41M$9.85M
Financing cash flow$30.43M——$0$274,000——$0
Stock-based compensation$2.39M$3.69M$1.84M$1.69M$1.69M$1.60M$1.47M$1.53M

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.